AI Insight
A landmark EORTC randomized clinical trial with over 20 years of follow-up examined the effects of irradiating internal mammary and medial supraclavicular lymph nodes in breast cancer patients. The final results demonstrate that this regional lymph node radiation therapy reduces breast cancer-specific mortality, yet does not translate into a statistically meaningful improvement in overall survival. These findings underscore the critical importance of conducting very long-term follow-up studies, especially in patient populations with otherwise favorable prognoses.
Why it matters
These results may prompt clinicians to reconsider the risk-benefit balance of lymph node irradiation, as reducing cancer-specific death without improving overall survival suggests competing causes of death, possibly treatment-related side effects, may offset the oncological benefit. This has direct implications for refining radiotherapy protocols and improving quality-of-life outcomes for breast cancer patients.
Final results from a landmark EORTC randomized trial with more than 20 years of follow-up show that irradiation of the internal mammary and medial supraclavicular lymph nodes reduces breast cancer mortality but does not improve overall survival. The findings highlight the importance of very long-term follow-up when evaluating cancer treatments, particularly in patients with an otherwise favorable prognosis.
Source: Long-term trial challenges assumptions about lymph node radiation therapy in breast cancer